{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:06:48Z","timestamp":1781276808191,"version":"3.54.1"},"reference-count":59,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objectives: Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes mellitus (DM) with symptoms like intense pain and impaired quality of life. This condition has no treatment; instead, the pain is managed with various antidepressants, including duloxetine. The aim of this study is to analyze the evidence on the efficacy of duloxetine in the management of DPN. Methods: A systematic search in different databases was conducted using the keywords \u201cdiabetic neuropathy\u201d, \u201cduloxetine therapy\u201d, \u201cneuropathic pain\u201d, and \u201cDiabetes Mellitus\u201d. Finally, eight studies were included in this meta-analysis. Results: All articles comparing duloxetine at different doses vs. a placebo reported significant differences in favor of duloxetine on pain scales like 24 h Average Pain Severity (standardized mean difference [SMD] = \u22121.06, confidence interval [CI] = \u22121.09 to \u22121.03, and p &lt; 0.00001) and BPI Severity (SMD = \u22120.70, CI = \u22120.72 to \u22120.68, and p &lt; 0.00001), among others. A total of 75% of the meta-analyses of studies comparing duloxetine at different doses showed a tendency in favor of the 120 mg\/d dose. There were significant differences in favor of duloxetine when compared to routine care on the Euro Quality of Life (SMD = \u22120.04, CI = \u22120.04 to \u22120.03, and p &lt; 0.00001) and SF-36 Survey (SMD = \u22125.86, CI = \u22126.28 to \u22125.44, and p &lt; 0.00001) scales. There were no significant differences on the visual analog scale (VAS) when comparing duloxetine and gabapentin. Conclusions: Duloxetine appears to be effective in the management of DPN in different pain, symptom improvement, and quality of life scales.<\/jats:p>","DOI":"10.3390\/ph17070856","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:04:18Z","timestamp":1719986658000},"page":"856","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Duloxetine versus Other Therapeutic Modalities in Patients with Diabetic Neuropathic Pain: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"17","author":[{"given":"Juan Jos\u00e9","family":"Valenzuela-Fuenzalida","sequence":"first","affiliation":[{"name":"Departamento de Morfolog\u00eda, Facultad de Medicina, Universidad Andr\u00e9s Bello, Santiago 8370146, Chile"},{"name":"Departamento de Ciencias Qu\u00edmica y Biol\u00f3gicas, Facultad de Ciencias de la Salud, Universidad Bernardo O\u2019Higgins, Santiago 8370993, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"L\u00f3pez-Chaparro","sequence":"additional","affiliation":[{"name":"Departamento de Morfolog\u00eda, Facultad de Medicina, Universidad Andr\u00e9s Bello, Santiago 8370146, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Barahona-V\u00e1squez","sequence":"additional","affiliation":[{"name":"Departamento de Morfolog\u00eda, Facultad de Medicina, Universidad Andr\u00e9s Bello, Santiago 8370146, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javiera","family":"Campos-Valdes","sequence":"additional","affiliation":[{"name":"Departamento de Morfolog\u00eda, Facultad de Medicina, Universidad Andr\u00e9s Bello, Santiago 8370146, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javiera","family":"Cordero Gonzalez","sequence":"additional","affiliation":[{"name":"Departamento de Morfolog\u00eda, Facultad de Medicina, Universidad Andr\u00e9s Bello, Santiago 8370146, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-0224","authenticated-orcid":false,"given":"Pablo","family":"Nova-Baeza","sequence":"additional","affiliation":[{"name":"Departamento de Morfolog\u00eda, Facultad de Medicina, Universidad Andr\u00e9s Bello, Santiago 8370146, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Orellana-Donoso","sequence":"additional","affiliation":[{"name":"Departamento de Morfolog\u00eda, Facultad de Medicina, Universidad Andr\u00e9s Bello, Santiago 8370146, Chile"},{"name":"Escuela de Medicina, Universidad Finis Terrae, Santiago 7501015, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Suazo-Santiba\u00f1ez","sequence":"additional","affiliation":[{"name":"Faculty of Health and Social Sciences, Universidad de Las Am\u00e9ricas, Santiago 8370040, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Oyanedel-Amaro","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Aut\u00f3noma de Chile, Santiago 7501019, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4650-3426","authenticated-orcid":false,"given":"H\u00e9ctor","family":"Guti\u00e9rrez Espinoza","sequence":"additional","affiliation":[{"name":"One Health Research Group, Universidad de las Americas, Quito 170124, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic Diabetic Ketoacidosis: A Review","volume":"13","author":"Modi","year":"2017","journal-title":"Curr. Diabetes Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11892-011-0176-0","article-title":"Nutrition therapy and the management of obesity and diabetes: An update","volume":"11","author":"Arathuzik","year":"2011","journal-title":"Curr. Diab. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Khunti","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2100275","DOI":"10.1002\/advs.202100275","article-title":"Emerging Targets in Type 2 Diabetes and Diabetic Complications","volume":"8","author":"Demir","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"Heerspink","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jdi.13462","article-title":"Imaging the eye and its relevance to diabetes care","volume":"12","author":"Quinn","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2982.2007.01023.x","article-title":"Diabetes and the enteric nervous system","volume":"19","author":"Chandrasekharan","year":"2007","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00019053-200422060-00005","article-title":"Repaglinide: A pharmacoeconomic review of its use in type 2 diabetes mellitus","volume":"22","author":"Plosker","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"ref_9","unstructured":"Swedish Council on Health Technology Assessment (2004). Moderately Elevated Blood Pressure: A Systematic Review, Swedish Council on Health Technology Assessment (SBU)."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/j.pain.0000000000001922","article-title":"Diabetic neuropathy and neuropathic pain: A (con)fusion of pathogenic mechanisms?","volume":"161","author":"Calcutt","year":"2020","journal-title":"Pain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e023600","DOI":"10.1136\/bmjopen-2018-023600","article-title":"Benefits and harms of pregabalin in the management of neuropathic pain: A rapid review and meta-analysis of randomised clinical trials","volume":"9","author":"Onakpoya","year":"2019","journal-title":"BMJ Open."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/dmrr.359","article-title":"Neuropathic pain and diabetes","volume":"19","author":"Kapur","year":"2003","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.117.014399","article-title":"Etiology and Pharmacology of Neuropathic Pain","volume":"70","author":"Alles","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain. Res. Manag."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/BOR.0b013e3282fb0268","article-title":"Pain management in fibromyalgia","volume":"20","author":"Crofford","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11916-022-01061-7","article-title":"Evidence-Based Treatment of Painful Diabetic Neuropathy: A Systematic Review","volume":"26","author":"Barman","year":"2022","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"154867","DOI":"10.1016\/j.metabol.2021.154867","article-title":"Management of diabetic neuropathy","volume":"123","author":"Cernea","year":"2021","journal-title":"Metabolism"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Plested, M., Budhia, S., and Gabriel, Z. (2010). Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: A systematic review. BMC Neurol., 10.","DOI":"10.1186\/1471-2377-10-116"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11096-023-01593-x","article-title":"Effect of duloxetine on pain and opioid consumption after total knee and hip arthroplasty: A systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Zhong","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_21","unstructured":"Eldridge, S., Campbell, M.K., Campbell, M.J., and Revised Cochrane Risk of Bias Tool for Randomized Trials (RoB2) (2024, June 10). Additional Considerations for Cluster-Randomized Trials (RoB 2 CRT). Available online: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1037\/a0024338","article-title":"Effect size estimates: Current use, calculations, and interpretation","volume":"141","author":"Fritz","year":"2012","journal-title":"J. Exp. Psychol. Gen."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/ijcp.12641","article-title":"Treatment of patients with diabetic peripheral neuropathic pain in China: A double-blind randomised trial of duloxetine vs. placebo","volume":"69","author":"Gao","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine vs. placebo in patients with painful diabetic neuropathy","volume":"116","author":"Goldstein","year":"2005","journal-title":"Pain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/1753-0407.13148","article-title":"A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy","volume":"13","author":"Khasbage","year":"2020","journal-title":"J. Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2147\/DDDT.S185995","article-title":"A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy","volume":"13","author":"Majdinasab","year":"2019","journal-title":"Drug. Des. Devel Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","article-title":"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain","volume":"6","author":"Raskin","year":"2005","journal-title":"Pain Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/jpm.2006.9.29","article-title":"Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain","volume":"9","author":"Raskin","year":"2006","journal-title":"J. Palliat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","article-title":"A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain","volume":"67","author":"Wernicke","year":"2006","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1526-4637.2006.00258.x","article-title":"An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain","volume":"8","author":"Wernicke","year":"2007","journal-title":"Pain Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1185\/03007991003769241","article-title":"Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: A meta-analysis","volume":"26","author":"Crucitti","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4084420","DOI":"10.1155\/2022\/4084420","article-title":"Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis","volume":"2022","author":"Jiang","year":"2022","journal-title":"Contrast. Media Mol. Imaging."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Quilici, S., Chancellor, J., L\u00f6thgren, M., Simon, D., Said, G., Le, T.K., Garcia-Cebrian, A., and Monz, B. (2009). Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol., 9.","DOI":"10.1186\/1471-2377-9-6"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1526-4637.2007.00276.x","article-title":"Duloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes","volume":"8","author":"Armstrong","year":"2007","journal-title":"Pain Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.2010.484418","article-title":"Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: Analysis of pooled data from three placebo-controlled clinical trials","volume":"9","author":"Hall","year":"2010","journal-title":"Expert. Opin. Drug. Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.clinthera.2007.12.002","article-title":"Duloxetine for the management of diabetic peripheral neuropathic pain: Evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies","volume":"29","author":"Kajdasz","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions--individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"Eur. J. Pain"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1526-4637.2007.00305.x","article-title":"Duloxetine for the management of diabetic peripheral neuropathic pain: Response profile","volume":"8","author":"Pritchett","year":"2007","journal-title":"Pain Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2337\/dc06-2009","article-title":"Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain","volume":"30","author":"Ziegler","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Duloxetine: Clinical pharmacokinetics and drug interactions","volume":"50","author":"Knadler","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_41","unstructured":"Dhaliwal, J.S., Spurling, B.C., and Molla, M. (2024). Duloxetine. 2023 May 29. StatPearls, StatPearls Publishing."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.pain.2014.08.020","article-title":"Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study","volume":"155","author":"Bouhassira","year":"2014","journal-title":"Pain."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2337\/dc12-0656","article-title":"Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life","volume":"35","author":"Boyle","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1185\/03007995.2013.784191","article-title":"Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions","volume":"29","author":"Gaynor","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/ijcp.12452","article-title":"Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain","volume":"68","author":"Irving","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/dc10-1793","article-title":"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: A randomized, double-blind, cross-over clinical trial","volume":"34","author":"Kaur","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ejp.763","article-title":"Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?","volume":"20","author":"Marchettini","year":"2016","journal-title":"Eur. J. Pain"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1526-4637.2006.00207.x","article-title":"Duloxetine for patients with diabetic peripheral neuropathic pain: A 6-month open-label safety study","volume":"7","author":"Raskin","year":"2006","journal-title":"Pain Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/cpdd.759","article-title":"The Effect of Food on the Single-Dose Bioavailability and Tolerability of the Highest Marketed Strength of Duloxetine","volume":"9","author":"Duna","year":"2020","journal-title":"Clin. Pharmacol. Drug. Dev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/dmrr.1000","article-title":"Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain","volume":"25","author":"Skljarevski","year":"2009","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"E578","DOI":"10.1097\/BRS.0b013e3181d3cef6","article-title":"Efficacy and safety of duloxetine in patients with chronic low back pain","volume":"35","author":"Skljarevski","year":"2010","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4065\/mcp.2010.0681","article-title":"Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: An open-label, randomized, noninferiority comparison","volume":"86","author":"Tanenberg","year":"2011","journal-title":"Mayo Clin, Proc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/papr.12121","article-title":"Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis","volume":"14","author":"Tanenberg","year":"2014","journal-title":"Pain Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: High-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d\u2014A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jdiacomp.2008.07.004","article-title":"Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions","volume":"23","author":"Wernicke","year":"2009","journal-title":"J. Diabetes Complicat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jpain.2006.01.443","article-title":"Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain","volume":"7","author":"Wu","year":"2006","journal-title":"J. Pain."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.pain.2012.02.021","article-title":"Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy","volume":"153","author":"Yarnitsky","year":"2012","journal-title":"Pain"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/jdi.12361","article-title":"Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study","volume":"7","author":"Yasuda","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/j.1532-2149.2012.00209.x","article-title":"Population pharmacokinetic\/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain","volume":"17","author":"Yuen","year":"2013","journal-title":"Eur. J. Pain"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/856\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:26Z","timestamp":1760108846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ph17070856"],"URL":"https:\/\/doi.org\/10.3390\/ph17070856","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}